BioNexus Gene Lab Corp
www.bionexusgenelab.comAI Executive Summary
AI-powered analysis of 10-Q filing content
BioNexus Gene Lab Corp shows deteriorating liquidity with cash declining 44% from $2.38M to $1.34M in Q1 2026. The company operates across diagnostics, specialty chemicals, CDMO services, and has added digital asset treasury strategies. Increasing allowance for credit losses suggests collection challenges, though fixed deposits increased indicating some cash management efforts.
Red Flags Detected (4)
Cash and bank balances decreased 44% from $2,383,369 to $1,337,554 in three months
Allowance for credit losses increased 25% from $703,995 to $878,903
Trade receivables from related party dropped to zero from $31,420
1 more red flag detected
Key Takeaways
Rapid cash depletion of over $1M in one quarter raises sustainability questions
Diversified business model spans diagnostics, chemicals, CDMO, and digital assets
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.